Sign up
Pharma Capital

Clinigen Group 'well positioned' to deliver another year of good progress

Shaun Chilton, chief executive of Clinigen Group PLC (LON:CLIN), tells Proactive second-half trading so far is in line with expectations following the release of the firm's interims today which reveal a solid performance in the first six months of the trading year.

Top line growth had been well flagged in an update last month with revenues ahead 28% at £167.8mln for the period ended December 31.


View full CLIN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.